at the simplest level, the particular gene, and particular perturberance, sets the "type" of cancer.
there will most often be additional genetic abnormalities giving nuance to the character of the oncotype.
the tumour is originated from a cell type of specific differentiation, and developmental potency, further widening the pool of possible cancer type.
immunotype of cancer also sets the relationship between cancer and the body.
the cells of the body are setup for a functional death and replacement so when you try to rescue a particular cell [or cohort] you are fighting against how the grand scheme of tissue maintenance operates.
unless you have concern for a particular long lived cell, it is best to destroy the tumour cell, and let the next cells in line replace them.
it is still a multifacet strategy being developed, inhibit the genetic properties of the tumour, and target the immunotype for destruction.
>would resistance also potentially cripple the cancer cells?<
this is the concept of genetic baggage, and metabolic budget.
there is only so much energy to a cell, and scant amounts to "waste" on preservation of something that is not used. in the long term, carrying unused properties are disadvantageous, and reduce reproductive output [replication]
the result is "unfettered" oncocytes outgrow those with baggage, and occlude access to resource. if there is no challange that reduces population of nonresistant cells, the resistance will be minimized and extinct in the face of large disparity of success.
evolution isnt about generating a response to a challenge, its about differential success.
those cells [oncocytes] that have properties conferring resistance carry it as un-utilized baggage, those without said properties make a living without that fetter.
the selective factor comes into play when payloaded LNP [in this case] facillitates destruction of "nonresistant" oncocytes and spare the "resistant"
the resistance is not generated in response to the challenge, it is already present, and confers survivorship in the face of the administration of the drug.
if anything i would use EXIF data to enhance stego.
generally its the JPEG standard that allows the payload, manipulation by abusing EXIF is how you operate the exploit.
there is a 64k file segment specified for JPEG, and you can abuse it to hold any "data" you want, as well as extending to other segments, for more storage.
the raw steganography in most primative form is a comparison of two photos, one of which is pixelshifted to encode the data.
in advanced form, the pixels hold the encrypted data, but the application segments of the JPEG hold keys and or matrix values, and you need a reference image. you can move fairly large volumes of ASCII representation like this before its noticed
you basicly write a webpage that local caches the payload and keys, then abuses EXIF to build and execute an exploit on the target.
https://en.wikipedia.org/wiki/Oncogene
at the simplest level, the particular gene, and particular perturberance, sets the "type" of cancer.
there will most often be additional genetic abnormalities giving nuance to the character of the oncotype.
the tumour is originated from a cell type of specific differentiation, and developmental potency, further widening the pool of possible cancer type.
immunotype of cancer also sets the relationship between cancer and the body.
the cells of the body are setup for a functional death and replacement so when you try to rescue a particular cell [or cohort] you are fighting against how the grand scheme of tissue maintenance operates.
unless you have concern for a particular long lived cell, it is best to destroy the tumour cell, and let the next cells in line replace them.
it is still a multifacet strategy being developed, inhibit the genetic properties of the tumour, and target the immunotype for destruction.
https://en.wikipedia.org/wiki/Cancer_immunology
reply